• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab beyond progression in HER2-positive metastatic breast cancer.

作者信息

Al-Naqqash Manwar, Jasim Al-Serarati Waleed, Farooq Kareem Tara

机构信息

Department of Surgery, College of Medicine, University of Baghdad, Baghdad, Iraq.

Department of Radiation Oncology, Oncology Teaching Hospital, Baghdad Medical City Complex, Ministry of Health/Environment, Baghdad, Iraq.

出版信息

Breast J. 2021 Mar;27(3):297-299. doi: 10.1111/tbj.14157. Epub 2021 Jan 20.

DOI:10.1111/tbj.14157
PMID:33472271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8247876/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53c1/8247876/75052a2650d0/TBJ-27-297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53c1/8247876/11ccf83f29e5/TBJ-27-297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53c1/8247876/75052a2650d0/TBJ-27-297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53c1/8247876/11ccf83f29e5/TBJ-27-297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53c1/8247876/75052a2650d0/TBJ-27-297-g001.jpg

相似文献

1
Trastuzumab beyond progression in HER2-positive metastatic breast cancer.曲妥珠单抗用于HER2阳性转移性乳腺癌进展后的治疗
Breast J. 2021 Mar;27(3):297-299. doi: 10.1111/tbj.14157. Epub 2021 Jan 20.
2
A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer.
Breast J. 2020 Sep;26(9):1903-1905. doi: 10.1111/tbj.13853. Epub 2020 May 7.
3
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.血清HER2/neu在接受曲妥珠单抗治疗的转移性乳腺癌患者无进展生存期监测及预测中的临床应用
Breast Cancer Res. 2005;7(4):R436-43. doi: 10.1186/bcr1020. Epub 2005 Apr 8.
4
HER2-positive metastatic breast cancer: a changing scenario.人表皮生长因子受体2阳性转移性乳腺癌：不断变化的情况。
Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi: 10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20.
5
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.曲妥珠单抗（赫赛汀）治疗转移性乳腺癌的疗效概述。
Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7.
6
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌之外的新兴方法。
Ann Oncol. 2013 Oct;24(10):2492-2500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4.
7
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.曲妥珠单抗作为 HER2 阳性转移性乳腺癌患者的一线治疗药物。
Expert Rev Anticancer Ther. 2012 Nov;12(11):1391-405. doi: 10.1586/era.12.107. Epub 2012 Oct 16.
8
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.曲妥珠单抗-美坦新偶联物对比医师选择的治疗方案用于治疗既往接受过治疗的人表皮生长因子受体 2（HER2）阳性转移性乳腺癌患者（TH3RESA）：一项随机、开放性、III 期临床试验的最终总生存结果。
Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16.
9
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.用于克服HER2阳性乳腺癌中曲妥珠单抗耐药性的个性化药物组合。
Biochim Biophys Acta. 2014 Dec;1846(2):353-65. doi: 10.1016/j.bbcan.2014.07.007. Epub 2014 Jul 25.
10
What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?转移性乳腺癌曲妥珠单抗联合化疗的最佳选择是什么？
Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167.

本文引用的文献

1
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544.
3
The global burden of women's cancers: a grand challenge in global health.女性癌症的全球负担：全球健康领域的一项重大挑战。
Lancet. 2017 Feb 25;389(10071):847-860. doi: 10.1016/S0140-6736(16)31392-7. Epub 2016 Nov 1.
4
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?HER2阳性转移性乳腺癌的一线治疗：这幅拼图是否已完整拼凑完成，还是我们仍遗漏了其他部分？
J Exp Clin Cancer Res. 2016 Jun 30;35:104. doi: 10.1186/s13046-016-0380-5.
5
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.曲妥珠单抗用于人表皮生长因子受体2阳性晚期乳腺癌进展后的治疗：德国乳腺癌研究组26/国际乳腺癌研究组03-05研究
J Clin Oncol. 2009 Apr 20;27(12):1999-2006. doi: 10.1200/JCO.2008.19.6618. Epub 2009 Mar 16.
6
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.疾病进展后继续使用曲妥珠单抗：转移性乳腺癌患者的结局分析
Breast Cancer Res. 2008;10(4):R60. doi: 10.1186/bcr2119. Epub 2008 Jul 16.
7
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.在基于曲妥珠单抗的治疗期间病情进展的HER2阳性晚期乳腺癌患者的结局
Oncologist. 2006 Apr;11(4):318-24. doi: 10.1634/theoncologist.11-4-318.
8
Global trends in breast cancer incidence and mortality 1973-1997.1973 - 1997年全球乳腺癌发病率和死亡率趋势
Int J Epidemiol. 2005 Apr;34(2):405-12. doi: 10.1093/ije/dyh414. Epub 2005 Feb 28.
9
Tumour biology: herceptin acts as an anti-angiogenic cocktail.肿瘤生物学：赫赛汀起到抗血管生成混合物的作用。
Nature. 2002 Mar 21;416(6878):279-80. doi: 10.1038/416279b.
10
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.对于过度表达HER2的转移性乳腺癌，使用化疗加一种抗HER2单克隆抗体进行治疗。
N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.